Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HDAC1 has strong prognostic impact in prostate cancer and might contribute to the development of a fraction of genetically instable and particularly aggressive prostate cancers.
|
25794974 |
2015 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetylases (HDACs), especially HDAC1, 2, 3 and 4, are abundantly expressed and over-activated in prostate cancer that is correlated with the poor prognosis.
|
28112184 |
2017 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
|
16914734 |
2006 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.
|
22797919 |
2012 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This is the first report demonstrating that CXXC sequence containing MBD1 is overexpressed and can be the major factor of hypermethylated chromatin segments through HDAC1/2 translocation and histone deacetylation in human prostate cancer.
|
12646234 |
2003 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
|
17079440 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our results support a model in which YY1 is able to silence tumor suppressor genes such as XAF1 through HDAC1 in PCa.
|
30551877 |
2019 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data indicate that MCP30 selectively induces PIN and PCa apoptosis and inhibits HDAC-1 activity.
|
19384952 |
2009 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, our findings indicate that epithelial and stromal cells exhibit distinct class I HDAC expression profiles, and the abundance of HDAC1 is not altered in human prostate cancer.
|
15590418 |
2005 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.
|
19252524 |
2009 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This is the first report to demonstrate that DNMT1 and HDAC1 levels are up-regulated in prostate cancer compared to BPH, suggesting their roles in inactivation of various genes, by DNA-methylation-induced chromatin-remodeling, in prostate cancer.
|
11563853 |
2001 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypermethylation of APC, HDAC1, and GSK1 genes has been previously reported in more than one study on tissue samples of breast cancer.
|
28349825 |
2017 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
|
25801958 |
2015 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that HDAC1 over-expression did not correlate with disease-free survival (DFS) and overall survival (OS) in breast cancer.
|
29738697 |
2018 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also found that the expression level of HDACs 1-3 was higher in breast cancer cell lines than in normal breast epithelial cells.
|
17230502 |
2007 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer.
|
12789259 |
2003 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
|
25173798 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study is the first to investigate the combinatorial effects of low physiologically achievable concentrations of WA and SFN on breast cancer cell proliferation, histone deacetylase1 (HDAC1) and DNA methyltransferases (DNMTs).
|
28534825 |
2017 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results imply that HDAC1 mRNA expression could have potential as an endocrine response marker and may have prognostic implications for breast cancer progression.
|
16172792 |
2005 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we sought to investigate the CSC-specific function of HDAC1 and HDAC7 mechanistically by using a stem-like breast cancer (BrCa) cell model BPLER and matched nonstem tumor cell (nsTC)-like HMLER, along with conventional BrCa cell lines with different CSC enrichment levels.
|
31375747 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, repression complex including DNMT1, HDAC1 and MeCP2 is only associated with silenced ESR1 in ER-negative MDA-MB-468 human breast cancer cells.
|
21655924 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.
|
23421821 |
2013 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It has also been found that CPF affects HDAC1 mRNA levels in mammary tissue pointing that CPF may act as a breast cancer risk factor.
|
30290214 |
2019 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subcellular localization of maspin protein and HDAC1 mRNA expression level in two human breast cancer cell lines (MCF7, MDA-MB-231) and mammary epithelial cell line (MCF10) were analyzed by immunofluorescence and quantitative polymerase chain reaction, respectively.
|
28870936 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings validate that 32c is a potent dual inhibitor of HDAC1/6 that can be an efficacious treatment for breast cancer with Adriamycin resistance.
|
30251407 |
2019 |